This Perspective is a continuation of our analysis of US FDA-approved small-molecule drugs
(1938–2012) containing nitrogen heterocycles. In this study we report drug structure and …

Benzenes, the most ubiquitous structural moiety in marketed small-molecule drugs, are
frequently associated with poor 'drug-like'properties, including metabolic instability, and poor …

The benzene moiety is the most prevalent ring system in marketed drugs, underscoring its
historic popularity in drug design either as a pharmacophore or as a scaffold that projects …

The design of bioisosteres represents a creative and productive approach to improve a
molecule, including by enhancing potency, addressing pharmacokinetic challenges …

Phenols and phenolic ethers are significant scaffolds recurring both in nature and among
approved small-molecule pharmaceuticals. This compendium presents the first …

DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …

Highlights•Drug-likeness refers to the similarity between compounds and drugs; drug-like
compounds are more likely to be transformed into drugs.•Chemical structures with enhanced …

A quaternary carbon bears four other carbon substituents or combination of four non-
hydrogen substituents at four vertices of a tetrahedron. The spirocyclic quaternary carbon …

The case for a renewed focus on Nature in drug discovery is reviewed; not in terms of
natural product screening, but how and why biomimetic molecules, especially those …

Two decades have passed since the rule of five ushered in the concept of “drug-like”
properties. Attempts to quantify, correlate, and categorize molecules based on Ro5 …